WO2013184061A1 - Medical use of particles of titanium and/or titanium oxide - Google Patents

Medical use of particles of titanium and/or titanium oxide Download PDF

Info

Publication number
WO2013184061A1
WO2013184061A1 PCT/SE2013/050620 SE2013050620W WO2013184061A1 WO 2013184061 A1 WO2013184061 A1 WO 2013184061A1 SE 2013050620 W SE2013050620 W SE 2013050620W WO 2013184061 A1 WO2013184061 A1 WO 2013184061A1
Authority
WO
WIPO (PCT)
Prior art keywords
particles
titanium
present
particles according
medical product
Prior art date
Application number
PCT/SE2013/050620
Other languages
French (fr)
Inventor
Lars-Magnus Bjursten
Sven-Erik Nilsson
Original Assignee
Migrata U.K. Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Migrata U.K. Limited filed Critical Migrata U.K. Limited
Priority to IN11097DEN2014 priority Critical patent/IN2014DN11097A/en
Priority to CN201380029110.4A priority patent/CN104736184A/en
Priority to US14/405,489 priority patent/US20150139913A1/en
Priority to EP13799808.4A priority patent/EP2854868A4/en
Publication of WO2013184061A1 publication Critical patent/WO2013184061A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres

Definitions

  • the present invention relates to medical use of particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof.
  • WO00/64504 discloses a biocompatible, plastic or essentially non- elastic, porous body, such as a grain, with continuous porosity, the openings of cavities and the passages interconnecting them having a width of > about 50 pm for bone tissue.
  • continuous is said to mean a porosity which allows bone tissue to grow through the porous body.
  • the porous body may be of titanium.
  • the grains may be used for providing ingrowth and growth of connective tissue as well as growth of other ceil types leading to duster of cells, tissues and parts of organs.
  • particles of rnicrostructure comprising titanium, titanium alloy, at least one titanium oxide or a combination thereof and their use in some medical applications are described.
  • the disclosed particles have a surface with at least a substantial part consisting of at least one type of titanium oxide.
  • the particles are brought into contact with at least one infected site in a human or animal body by insertion, injection or implantation.
  • the infected site exhibits the inflammatory and/or bacterial condition.
  • WO 2008/103082 refers to an injectable suspension comprising the particles and a fluid vehicle for use as a medicament.
  • conditions being treated with the injectable suspension are periodontitis, periimplantitis, and osteitis. Due to the fact of the small size of the particles, these could easily be brought into contact with an infected site present in the human or animal body. Specific examples are infected sites in the mouth or close to the teeth, that is for dental applications, but also e.g. in the intestine or other organs or tissues. An important example is bone tissue.
  • the particles of micro- structure or the injectable suspension disclosed in WO 2008/103082 may also be injected into or inserted into non-infiamed and/or non-infected sites of a human or animal body. e.g. the intestine, liver, spleen, pancreas or the kidneys.
  • a human or animal body e.g. the intestine, liver, spleen, pancreas or the kidneys.
  • One example of use of the particles of microstructure or the injectable suspension are as carriers of medicaments to specific parts of the human or animal body, where the particles either work just as a carriers or as active medicaments in combination with the other medicaments at the site intended to be contacted.
  • One aim of the present invention is to provide a novel medical use for particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof.
  • the present invention providing particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof, wherein at least a substantial amount of the particles are of micrometer - millimeter size and are non-spherical, for use as an X-ray contrast agent.
  • the particles are of micrometer - millimeter size. In relation to the present invention, this implies that the particles have a "diameter" in the range of 10 pm - 5 mm, such as in the range of 10 pm - 2 mm, where most of them have a diameter in the range of 10 pm - 0.5 mm.
  • the particles according to the present invention are not perfect spheres. Therefore, according to one specific embodiment of the present invention, being non-spherical implies that they have internal pores or cavities or have an irregular shape.
  • the pores may be so called continuous pores going through the particles from one side to the other side, implying at least two openings on the surface of the particle. The pores may also resemble caves with only one opening on the particle surface.
  • These caves may also be pores going deep inside of the particle but not through the entire structure. These caves may be of different length, stretching from one side of the particle to the other side of the same particle or appear as pits on the surface of the particles.
  • the cavities may have an irregular shape and be that of a channel or hole inside the particle. Furthermore, there may also be provided cavities which are nearer the surface and not as deep.
  • the entire structure may have an irregular shape implying that the surface is wavy or also having a geometrical shape not being a sphere, such as having an elongated or asymmetrical cross section or the like. Structures incorporating all of the above features, such being almost oval, having continuous pores and an irregular surface and so on, are of course totally possible according to the present invention.
  • EP1 146072 discloses spherical particles having a particle size of 5 to 10,000 nm, containing 0.1 to 99.9 % by weight of a first oxidic compound, selected from for example titanium and silicon and at least one further oxide of the lanthanides.
  • the particles either have an onion-skin-like structure comprising layers of the different metal oxides or have a homogenous distribution of the metal oxides throughout the particle.
  • one or more metal oxides are embedded in a matrix of one or more metal oxides. Since the lanthanides are paramagnetic, the particles are suitable as an MRI contrast agent. In addition, the particles may also be used as X-ray contrast agents.
  • the particles of the present invention have irregular shapes, such as they are in the shape of spheres, spikes, flakes, chips or similar or combinations thereof.
  • the particles used according to the present invention have an irregular surface and/or internal pores and cavities. As described above, this will lead to a prolonged retention time in the
  • X-ray contrast agents are often based on barium or iodine.
  • Barium sulphate is used as contrast agent for the gastrointestinal tract and is administered per os or per rectum.
  • a problem associated with the use of barium sulphate as an X-ray contrast agent is the risk of side effects, such as allergic reactions, urticaria and indigestion, such as constipation or diarrhoea.
  • the particles according to the present invention are chemically inert, and are most unlikely to cause any severe adverse effects when administered per os or per rectum.
  • the particles of the present invention are not only chemically inert, they also exhibit an anti-inflammatory and anti-bacterial effect on surrounding tissue.
  • US4020152 there is disclosed another type of contrast agent, namely a radiological contrast product comprising a non-toxic radiopaque salt selected from the group consisting of barium titanate and barium zirconate.
  • the contrast agent disclosed is different from the present invention in many aspects. The first one is the actual material. The second aspect is the shape, both in terms of the actual geometrical shape and size, which are clearly stated features according to the present invention.
  • the above mentioned advantages of the particles according to the present invention such as being chemically inert and also exhibiting an anti-inflammatory and anti-bacterial effect on surrounding tissue, are not addressed or achieved by the material disclosed in US4020152.
  • the particles according to the present invention exhibit a relatively long retention time in the gastrointestinal tract. This is due to the irregular shape of the particles according to the present invention, leading the particles hitching to each other creating larger complexes which will have a prolonged retention time compared to an individual particle or to spherical particles of approximately the same size.
  • the material of the particles is essential in relation to the present invention. Firstly, it is the matter of the possible compositions of the particles, where titanium is an element always being present. However, it is important to understand that the base metal titanium can be present in a particle according to the present invention as an alloy, as pure metal titanium, that is with only possible small amounts of impurities, as a titanium oxide, or a combination thereof.
  • the possible small amounts of impurities in pure titanium are normally oxides or some metals, but could also consist of other chemicals.
  • titanium oxide is always present in some extent on the surface of the particles.
  • titanium oxides are titanium dioxide ( ⁇ 2), also known as titanium(IV) oxide or titania, titanium monoxide (TiO), also known as titanium(ll) oxide, dititanium trioxide ( ⁇ 2 ⁇ 3), also known as titanium(lll) oxide, Ti 3 0 and Ti 2 0.
  • titanium alloys include alloys comprising titanium and one or more of aluminium, gallium, germanium, carbon, oxygen, nitrogen, molybdenum, vanadium, tantalum, niobium, manganese, iron, chromium, cobalt, nickel, copper and silicon.
  • the particles are made of titanium dioxide.
  • Another most valid mixture is a set of grains of titanium dioxide particles and titanium metal particles, and possibly also particles being of metal but having a relatively extensive oxide surface coating.
  • the particles are non-spherical implying having e.g. irregular shapes, that is they are in the shape of spheres, spikes, flakes, chips or similar or combinations thereof.
  • the particles used according to the present invention have irregular surfaces, i.e. they have internal pores, e.g. continuous such, or cavities.
  • the particles used as an X-ray contrast agent are non-spherical and have an average length from one side to the opposite side, through a geometrical centre, of ⁇ 5 mm. According to one specific embodiment of the present invention, the particles have an average length from one side to the opposite side, through a geometrical centre, of in the range of ⁇ 2 mm, more
  • the particles used according to the present invention have an average length from one side to the opposite side, through a geometrical centre, of ⁇ 0.5 mm, even more specifically of ⁇ 0.2 mm and still more specific of ⁇ 0.1 mm.
  • the particles used as an X-ray contrast agent have an average length from one side to the opposite side, through a geometrical centre, in the range of 0.01 -0.1 mm, more specifically an average length from one side to the opposite side, through a geometrical centre, of
  • the particles used according to the present invention may be present as a mixture of particles having different average length from one side to the opposite side, through a geometrical centre, that is the size distribution of the used particles may be in the range of 0.01 mm - 5 mm.
  • the particles are contained in a medical product in the form of a solution, dispersion, suspension, a tablet, a pastille, a suppository, or any other dosage form intended for oral or rectal administration.
  • the products for oral administration may be consumed for example as a liquid, a tablet for swallowing or a chewing tablet.
  • the medical product according to the present invention may also comprise at least one functional additive, which may be directed to affecting the physical properties of the medical product. Examples are additives like dispersants, emulsifiers or gelatinizing agents, or an agent increasing the surface tension, making sure that the product has the correct form or physical properties for a specific administration.
  • Another possibility is to add a dry mixture of a weak acid and a weak base so that the particles are dispersed by the carbon dioxide gas that is released when the mixture comes in contact with the wet environment of the gastrointestinal tract.
  • the medical product used as an X-ray contrast agent also comprises at least one functional additive directed to affecting the therapeutic properties of the medical product.
  • functional additives directed to affecting the therapeutic properties of the medical product may be used in the same medical product.
  • antibiotics and anti-inflammatory agents may both be present in the medical product to be used according to the present invention.
  • the particles are used as an inert X-ray contrast agent in the gastrointestinal tract of a human or animal.
  • the usage is intended to leave the human or animal gastrointestinal tract unaffected by the use of the particles.
  • the particles used as an X-ray contrast agent are used for monitoring the therapeutic effect of the particles when administered into the human or animal body.
  • the location of the particles and the status of the surrounding tissue are
  • the particles can be present in a medical product also comprising a compound having therapeutic effect. Since the particles, according to the present invention, are used as an X-ray contrast agent, the location of the particles in the medical product can be determined by X-ray examination at the same time as the effect of the compound having therapeutic effect on status of the surrounding tissue is examined. The therapy can hence be evaluated with regard to how much of the particles (that is the medical product also comprising a compound) having therapeutic effect actually reach the site intended.

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention describes particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof, wherein at least a substantial amount of the particles are of micrometer - millimeter size and are non-spherical, for use as an X-ray contrast agent. The irregular shapes and/or internal pores and cavities of said particles lead to a prolonged retention time in the gastrointestinal tract leading to a longer time period available for X-ray examination. Further, the particles are not only chemically inert, they also exhibit an anti-inflammatory and anti-bacterial effect on the surrounding tissue.

Description

MEDICAL USE OF PARTICLES OF TITANIUM AND/OR TITANIUM OXIDE
Field of the invention
The present invention relates to medical use of particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof. Technical Background
It has long been known that titanium, its oxides and alloys are biocompatible and hence are used in various medical applications. For example, WO00/64504 discloses a biocompatible, plastic or essentially non- elastic, porous body, such as a grain, with continuous porosity, the openings of cavities and the passages interconnecting them having a width of > about 50 pm for bone tissue. The term "continuous" is said to mean a porosity which allows bone tissue to grow through the porous body. The porous body may be of titanium. The grains may be used for providing ingrowth and growth of connective tissue as well as growth of other ceil types leading to duster of cells, tissues and parts of organs.
In WO 2008/103082 particles of rnicrostructure comprising titanium, titanium alloy, at least one titanium oxide or a combination thereof and their use in some medical applications are described. The disclosed particles have a surface with at least a substantial part consisting of at least one type of titanium oxide. The particles are brought into contact with at least one infected site in a human or animal body by insertion, injection or implantation. The infected site exhibits the inflammatory and/or bacterial condition.
Furthermore, WO 2008/103082 refers to an injectable suspension comprising the particles and a fluid vehicle for use as a medicament. Examples of conditions being treated with the injectable suspension are periodontitis, periimplantitis, and osteitis. Due to the fact of the small size of the particles, these could easily be brought into contact with an infected site present in the human or animal body. Specific examples are infected sites in the mouth or close to the teeth, that is for dental applications, but also e.g. in the intestine or other organs or tissues. An important example is bone tissue. In addition to being injected into inflamed and/or infected tissue, the particles of micro- structure or the injectable suspension disclosed in WO 2008/103082 may also be injected into or inserted into non-infiamed and/or non-infected sites of a human or animal body. e.g. the intestine, liver, spleen, pancreas or the kidneys. One example of use of the particles of microstructure or the injectable suspension are as carriers of medicaments to specific parts of the human or animal body, where the particles either work just as a carriers or as active medicaments in combination with the other medicaments at the site intended to be contacted.
One aim of the present invention is to provide a novel medical use for particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof.
Summary of the invention
The stated purpose above is achieved by the present invention providing particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof, wherein at least a substantial amount of the particles are of micrometer - millimeter size and are non-spherical, for use as an X-ray contrast agent.
According to the present invention, the particles are of micrometer - millimeter size. In relation to the present invention, this implies that the particles have a "diameter" in the range of 10 pm - 5 mm, such as in the range of 10 pm - 2 mm, where most of them have a diameter in the range of 10 pm - 0.5 mm. Furthermore, the particles according to the present invention are not perfect spheres. Therefore, according to one specific embodiment of the present invention, being non-spherical implies that they have internal pores or cavities or have an irregular shape. The pores may be so called continuous pores going through the particles from one side to the other side, implying at least two openings on the surface of the particle. The pores may also resemble caves with only one opening on the particle surface. These caves may also be pores going deep inside of the particle but not through the entire structure. These caves may be of different length, stretching from one side of the particle to the other side of the same particle or appear as pits on the surface of the particles. The cavities may have an irregular shape and be that of a channel or hole inside the particle. Furthermore, there may also be provided cavities which are nearer the surface and not as deep.
Moreover, the entire structure may have an irregular shape implying that the surface is wavy or also having a geometrical shape not being a sphere, such as having an elongated or asymmetrical cross section or the like. Structures incorporating all of the above features, such being almost oval, having continuous pores and an irregular surface and so on, are of course totally possible according to the present invention.
In contrast to the present invention, EP1 146072 discloses spherical particles having a particle size of 5 to 10,000 nm, containing 0.1 to 99.9 % by weight of a first oxidic compound, selected from for example titanium and silicon and at least one further oxide of the lanthanides. The particles either have an onion-skin-like structure comprising layers of the different metal oxides or have a homogenous distribution of the metal oxides throughout the particle. Alternatively, one or more metal oxides are embedded in a matrix of one or more metal oxides. Since the lanthanides are paramagnetic, the particles are suitable as an MRI contrast agent. In addition, the particles may also be used as X-ray contrast agents.
In contrast to the particles disclosed in EP1 146072, which are spherical, the particles of the present invention have irregular shapes, such as they are in the shape of spheres, spikes, flakes, chips or similar or combinations thereof. In addition, the particles used according to the present invention have an irregular surface and/or internal pores and cavities. As described above, this will lead to a prolonged retention time in the
gastrointestinal tract leading to a longer time period available for X-ray examination.
Conventional X-ray contrast agents are often based on barium or iodine. Barium sulphate is used as contrast agent for the gastrointestinal tract and is administered per os or per rectum. A problem associated with the use of barium sulphate as an X-ray contrast agent is the risk of side effects, such as allergic reactions, urticaria and indigestion, such as constipation or diarrhoea. In contrast to barium sulphate, the particles according to the present invention are chemically inert, and are most unlikely to cause any severe adverse effects when administered per os or per rectum. Furthermore, the particles of the present invention are not only chemically inert, they also exhibit an anti-inflammatory and anti-bacterial effect on surrounding tissue.
In US4020152 there is disclosed another type of contrast agent, namely a radiological contrast product comprising a non-toxic radiopaque salt selected from the group consisting of barium titanate and barium zirconate. The contrast agent disclosed is different from the present invention in many aspects. The first one is the actual material. The second aspect is the shape, both in terms of the actual geometrical shape and size, which are clearly stated features according to the present invention. Moreover, the above mentioned advantages of the particles according to the present invention, such as being chemically inert and also exhibiting an anti-inflammatory and anti-bacterial effect on surrounding tissue, are not addressed or achieved by the material disclosed in US4020152.
Moreover, the particles according to the present invention exhibit a relatively long retention time in the gastrointestinal tract. This is due to the irregular shape of the particles according to the present invention, leading the particles hitching to each other creating larger complexes which will have a prolonged retention time compared to an individual particle or to spherical particles of approximately the same size.
Specific embodiments according to the present invention will be described in more detail below. These embodiments should be regarded just as such specific ones, and should not be interpreted as a limitation of the present invention. The scope of the invention is defined by the appended claims.
Specific embodiments of the invention
The material of the particles is essential in relation to the present invention. Firstly, it is the matter of the possible compositions of the particles, where titanium is an element always being present. However, it is important to understand that the base metal titanium can be present in a particle according to the present invention as an alloy, as pure metal titanium, that is with only possible small amounts of impurities, as a titanium oxide, or a combination thereof. The possible small amounts of impurities in pure titanium are normally oxides or some metals, but could also consist of other chemicals. Moreover, titanium oxide is always present in some extent on the surface of the particles. Different types of possible titanium oxides are titanium dioxide (ΤΊΟ2), also known as titanium(IV) oxide or titania, titanium monoxide (TiO), also known as titanium(ll) oxide, dititanium trioxide (ΤΊ2Ο3), also known as titanium(lll) oxide, Ti30 and Ti20. Examples of titanium alloys include alloys comprising titanium and one or more of aluminium, gallium, germanium, carbon, oxygen, nitrogen, molybdenum, vanadium, tantalum, niobium, manganese, iron, chromium, cobalt, nickel, copper and silicon.
According to one specific embodiment of the present invention, the particles are made of titanium dioxide. Another most valid mixture is a set of grains of titanium dioxide particles and titanium metal particles, and possibly also particles being of metal but having a relatively extensive oxide surface coating.
Secondly, the geometrical structure and size are important. According to the present invention, the particles are non-spherical implying having e.g. irregular shapes, that is they are in the shape of spheres, spikes, flakes, chips or similar or combinations thereof. In addition, the particles used according to the present invention have irregular surfaces, i.e. they have internal pores, e.g. continuous such, or cavities.
According to one specific embodiment of the present invention, the particles used as an X-ray contrast agent are non-spherical and have an average length from one side to the opposite side, through a geometrical centre, of < 5 mm. According to one specific embodiment of the present invention, the particles have an average length from one side to the opposite side, through a geometrical centre, of in the range of < 2 mm, more
specifically an average length from one side to the opposite side, through a geometrical centre, of < 1 mm. More specifically, the particles used according to the present invention have an average length from one side to the opposite side, through a geometrical centre, of < 0.5 mm, even more specifically of < 0.2 mm and still more specific of < 0.1 mm. According to one specific embodiment of the present invention, the particles used as an X-ray contrast agent have an average length from one side to the opposite side, through a geometrical centre, in the range of 0.01 -0.1 mm, more specifically an average length from one side to the opposite side, through a geometrical centre, of
< 0.05 mm. It is important to appreciate that the particles used according to the present invention may be present as a mixture of particles having different average length from one side to the opposite side, through a geometrical centre, that is the size distribution of the used particles may be in the range of 0.01 mm - 5 mm.
According to one specific embodiment of the present invention, the particles are contained in a medical product in the form of a solution, dispersion, suspension, a tablet, a pastille, a suppository, or any other dosage form intended for oral or rectal administration. The products for oral administration may be consumed for example as a liquid, a tablet for swallowing or a chewing tablet. In order to facilitate the administration of the particles for use according to the present invention, the medical product according to the present invention may also comprise at least one functional additive, which may be directed to affecting the physical properties of the medical product. Examples are additives like dispersants, emulsifiers or gelatinizing agents, or an agent increasing the surface tension, making sure that the product has the correct form or physical properties for a specific administration. Another possibility is to add a dry mixture of a weak acid and a weak base so that the particles are dispersed by the carbon dioxide gas that is released when the mixture comes in contact with the wet environment of the gastrointestinal tract.
Moreover, according to one embodiment of the present invention, the medical product used as an X-ray contrast agent also comprises at least one functional additive directed to affecting the therapeutic properties of the medical product. Examples are antibiotics, anti-inflammatory agents, steroids, NSAID (non steroidal anti-inflammatory drug), drugs to treat diarrhoea or constipation. Different functional additives directed to affecting the therapeutic properties of the medical product may be used in the same medical product. For example, antibiotics and anti-inflammatory agents may both be present in the medical product to be used according to the present invention.
According to one embodiment of the present invention, the particles are used as an inert X-ray contrast agent in the gastrointestinal tract of a human or animal. The usage is intended to leave the human or animal gastrointestinal tract unaffected by the use of the particles.
According to one specific embodiment of the present invention, the particles used as an X-ray contrast agent are used for monitoring the therapeutic effect of the particles when administered into the human or animal body. By visualizing the administered particles by X-ray examination, the location of the particles and the status of the surrounding tissue are
determined. In this way, the therapeutic effect of administered particles can be monitored. As described above, according to the present invention, the particles can be present in a medical product also comprising a compound having therapeutic effect. Since the particles, according to the present invention, are used as an X-ray contrast agent, the location of the particles in the medical product can be determined by X-ray examination at the same time as the effect of the compound having therapeutic effect on status of the surrounding tissue is examined. The therapy can hence be evaluated with regard to how much of the particles (that is the medical product also comprising a compound) having therapeutic effect actually reach the site intended.

Claims

Claims
1 . Particles of titanium, titanium alloy, at least one type of titanium oxide or a combination thereof, wherein at least a substantial amount of the particles are of micrometer - millimeter size and are non-spherical, for use as an X-ray contrast agent.
2. Particles according to claim 1 , wherein non-spherical implies having internal pores or cavities or having an irregular shape.
3. Particles according to claim 1 or 2, wherein the particles are contained in a medical product in the form of a solution, dispersion, suspension, a tablet, a pastille, a suppository, or any other dosage form intended for oral or rectal administration.
4. Particles according to claim 3, wherein the medical product also comprises at least one functional additive.
5. Particles according to claim 4, wherein the at least one functional additive is directed to affecting the physical properties of the medical product.
6. Particles according to claim 4, wherein the at least one functional additive is directed to affecting the therapeutic properties of the medical product.
7. Particles according to any of claims 1 -6, wherein the particles are made of titanium dioxide.
8. Particles according to any of claims 1 -7, for use as an inert X-ray contrast agent for use in the gastrointestinal tract.
9. Particles according to any of claims 1 -8, for monitoring the therapeutic effect of said particles when administered into the human or animal body.
PCT/SE2013/050620 2012-06-04 2013-05-29 Medical use of particles of titanium and/or titanium oxide WO2013184061A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
IN11097DEN2014 IN2014DN11097A (en) 2012-06-04 2013-05-29
CN201380029110.4A CN104736184A (en) 2012-06-04 2013-05-29 Medical use of particles of titanium and/or titanium oxide
US14/405,489 US20150139913A1 (en) 2012-06-04 2013-05-29 Medical use of particles of titanium and/or titanium oxide
EP13799808.4A EP2854868A4 (en) 2012-06-04 2013-05-29 Medical use of particles of titanium and/or titanium oxide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261655093P 2012-06-04 2012-06-04
SE1250582 2012-06-04
SE1250582-2 2012-06-04
US61/655,093 2012-06-04

Publications (1)

Publication Number Publication Date
WO2013184061A1 true WO2013184061A1 (en) 2013-12-12

Family

ID=49712337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2013/050620 WO2013184061A1 (en) 2012-06-04 2013-05-29 Medical use of particles of titanium and/or titanium oxide

Country Status (5)

Country Link
US (1) US20150139913A1 (en)
EP (1) EP2854868A4 (en)
CN (1) CN104736184A (en)
IN (1) IN2014DN11097A (en)
WO (1) WO2013184061A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968619A4 (en) * 2013-03-15 2016-11-02 Univ California Enteric ct contrast material based on low-z atoms

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113456839B (en) * 2021-07-05 2022-06-21 浙江大学 Dipole resonance enhanced double-negative acoustic metamaterial and application thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020152A (en) * 1973-12-18 1977-04-26 Thann & Mulhouse Barium titanate and barium zirconate in radiological contrast products
EP0253554A2 (en) * 1986-07-15 1988-01-20 Pfizer Inc. Controlled release drug-containing fibers
US6024569A (en) * 1998-11-06 2000-02-15 Aytec Japan Corporation Root canal filling point
WO2000064504A2 (en) * 1999-04-28 2000-11-02 Bruce Medical Ab Body for providing ingrowth and growth of bone tissue and/or connective tissue and method of making such a body
EP1146072A1 (en) * 2000-04-13 2001-10-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Spheric oxidic particles, process for their preparation and their use
WO2002013876A2 (en) * 2000-08-15 2002-02-21 Carbon Medical Technologies Tissue marking using biocompatible microparticles
WO2003080144A1 (en) * 2002-03-22 2003-10-02 Kuros Biosurgery Ag Composition for hard tissue augmentation
WO2008103082A1 (en) * 2007-02-22 2008-08-28 Tigran Technologies Ab (Publ) Treatment of inflammatory and/or bacterial conditions with particles of microstructure
JP2008297289A (en) * 2007-06-04 2008-12-11 Canon Inc Contrast medium and production method thereof
WO2010039799A1 (en) * 2008-09-30 2010-04-08 Sabic Innovative Plastics Ip B.V. X-ray and/or metal detectable articles and method of making the same
WO2011084625A1 (en) * 2009-12-16 2011-07-14 Georgia Tech Research Corporation Systems and methods for x-ray flourescence computed tomography imaging with nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204388D0 (en) * 1992-02-29 1992-04-15 Tioxide Specialties Ltd Water-in-oil emulsions
US5593657A (en) * 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
JP4474878B2 (en) * 2003-09-17 2010-06-09 株式会社Ｉｈｉ X-ray contrast medium and method for producing X-ray contrast medium
JP2008518873A (en) * 2004-11-02 2008-06-05 ナノゲート エージー Synthesis of titanium dioxide nanoparticles
GB0921596D0 (en) * 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020152A (en) * 1973-12-18 1977-04-26 Thann & Mulhouse Barium titanate and barium zirconate in radiological contrast products
EP0253554A2 (en) * 1986-07-15 1988-01-20 Pfizer Inc. Controlled release drug-containing fibers
US6024569A (en) * 1998-11-06 2000-02-15 Aytec Japan Corporation Root canal filling point
WO2000064504A2 (en) * 1999-04-28 2000-11-02 Bruce Medical Ab Body for providing ingrowth and growth of bone tissue and/or connective tissue and method of making such a body
EP1146072A1 (en) * 2000-04-13 2001-10-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Spheric oxidic particles, process for their preparation and their use
WO2002013876A2 (en) * 2000-08-15 2002-02-21 Carbon Medical Technologies Tissue marking using biocompatible microparticles
WO2003080144A1 (en) * 2002-03-22 2003-10-02 Kuros Biosurgery Ag Composition for hard tissue augmentation
WO2008103082A1 (en) * 2007-02-22 2008-08-28 Tigran Technologies Ab (Publ) Treatment of inflammatory and/or bacterial conditions with particles of microstructure
JP2008297289A (en) * 2007-06-04 2008-12-11 Canon Inc Contrast medium and production method thereof
WO2010039799A1 (en) * 2008-09-30 2010-04-08 Sabic Innovative Plastics Ip B.V. X-ray and/or metal detectable articles and method of making the same
WO2011084625A1 (en) * 2009-12-16 2011-07-14 Georgia Tech Research Corporation Systems and methods for x-ray flourescence computed tomography imaging with nanoparticles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2854868A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968619A4 (en) * 2013-03-15 2016-11-02 Univ California Enteric ct contrast material based on low-z atoms
US11033640B2 (en) 2013-03-15 2021-06-15 The Regents Of The University Of California Enteric CT contrast material based on low-z atoms
EP3984560A1 (en) * 2013-03-15 2022-04-20 The Regents of the University of California Enteric ct contrast material based on low-z atoms

Also Published As

Publication number Publication date
US20150139913A1 (en) 2015-05-21
CN104736184A (en) 2015-06-24
EP2854868A4 (en) 2016-01-20
IN2014DN11097A (en) 2015-09-25
EP2854868A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
JP6017567B2 (en) Broad-spectrum antibacterial composition based on a combination of taurolidine and protamine and medical devices containing such a composition
Chaturvedi et al. Doxycycline poly e-caprolactone nanofibers in patients with chronic periodontitis–a clinical evaluation
Tran et al. Nanomaterial‐based treatments for medical device‐associated infections
Nayak et al. Calcium fluoride-based dental nanocomposites
Chandak et al. Nanoparticles in endodontics-a review
EP2854868A1 (en) Medical use of particles of titanium and/or titanium oxide
Yu et al. Epigallocatechin-3-gallate/mineralization precursors co-delivery hollow mesoporous nanosystem for synergistic manipulation of dentin exposure
Batra Applications of nanoparticles in orthodontics
Vahabi et al. Applications of nanotechnology in dentistry: a review
Pham et al. Nanoparticles-hydrogel composites: A promising innovative system for local antimicrobial applications
Deng et al. Evaluation of bond strength and microleakage of a novel metal-titanate antibacterial agent
Wang et al. Recent Progress in antibacterial hydrogel coatings for targeting biofilm to prevent orthopedic implant-associated infections
EP4129271A1 (en) Novel cerium oxide nanocomposite and use thereof
Zakrzewski Dobrzy nski
Florez et al. Orally delivered nanoparticle drug-delivery systems for dental applications and their systemic toxicity
JP4317606B2 (en) Solid particle forming composition
Verma et al. Nanotechnology in Endodontics: A Hope or Hype.
Hadi et al. Clinical Application of Iron Oxide Nanoparticles in Dentistry A Review
Makvandi et al. Polymeric and Nanoscopical antimicrobial fillers in dentistry
Afkhami et al. Application of Nanomaterials in Endodontics
US20230089986A1 (en) Novel cerium oxide nanocomplex and a composition for preventing or treating cerebral infarction comprising the same
JP2023519263A (en) Novel cerium oxide nanocomposites and their uses
Yuan et al. Biomineralization-Inspired Anti-Caries Strategy Based on Multifunctional Nanogels as Mineral Feedstock Carriers
Elmarsafy A Comprehensive Narrative Review of Nanomaterial Applications in Restorative Dentistry: Demineralization Inhibition and Remineralization Applications (Part I)
Ravinayagam et al. 11 Challenges of Materials

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13799808

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14405489

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2013799808

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013799808

Country of ref document: EP